bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE
September 14 2022 - 8:15AM
Business Wire
bioAffinity Technologies, (NASDAQ: BIAF, BIAFW), a biotechnology
company that develops noninvasive, early-stage diagnostics to
detect cancer and diseases of the lung, today announced publication
of its research in high-throughput flow cytometry analysis of
sputum. The journal PLOS ONE, published Sputum analysis by flow
cytometry; an effective platform to analyze the lung environment
reporting on results of analyzing sputum by flow cytometry as the
basis for high-throughput diagnostic tests to determine the health
of the lung.
“The PLOS ONE paper presents our unique method for determining
the health of an individual’s lungs,” bioAffinity President and CEO
Maria Zannes said. “Flow cytometry allows for analysis of whole
cells and cell populations that make up the lung environment. Our
research provides a better understanding of how disease changes the
lung environment and how flow cytometry can be used as a diagnostic
tool by analyzing sputum. Flow cytometry is successfully used to
diagnose blood cancers, particularly at early stage. In the paper,
we describe an innovative and highly efficient method to analyze
sputum for the presence of lung cancer, with the potential to focus
on other diseases such as COPD and asthma.”
bioAffinity Technologies is addressing the need for noninvasive
diagnosis of early-stage cancer and diseases of the lung, and
targeted cancer treatment. The Company develops proprietary
noninvasive diagnostic tests using technology that preferentially
targets cancer cells and cell populations indicative of a diseased
state. The Company’s first product, CyPath® Lung, is a non-invasive
test that has shown high sensitivity and specificity for the
detection of early-stage lung cancer. The test is marketed as a
Laboratory Developed Test (LDT) by Precision Pathology Services.
Research and optimization of the Company’s platform technologies
are conducted in its laboratories at The University of Texas at San
Antonio.
About CyPath® Lung
CyPath® Lung is a noninvasive test for the early detection of
lung cancer which uses flow cytometry to count and characterize
cells in a person’s sputum, or phlegm. The test’s automated
analysis of the flow cytometry data detects cell populations that
indicate cancer is present. CyPath® Lung has the potential to
increase overall diagnostic accuracy of lung cancer diagnosis
leading to increased survival while lowering the number of
unnecessary invasive procedures, reducing patient anxiety, and
lowering medical costs. CyPath® Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Services.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses
the need for noninvasive diagnosis of early-stage cancer and
diseases of the lung, and targeted cancer treatment. The Company’s
first product, CyPath® Lung, has shown high sensitivity and
specificity for detecting early-stage lung cancer. OncoSelect®
Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is
advancing its discoveries shown in vitro to kill cancer cells
without harm to normal cells. Research and optimization of the
Company’s platform technologies are conducted in its laboratories
at The University of Texas at San Antonio.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220914005215/en/
Company Contact: Maria Zannes,
President & Chief Executive Officer mz@bioaffinitytech.com
Investor Relations Contact:
Tiberend Strategic Advisors, Inc. Jonathan Nugent
jnugent@tiberend.com David Irish dirish@tiberend.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Mar 2024 to Apr 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Apr 2023 to Apr 2024